Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.12), $0.09 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.